937014-94-3

Basic information

• Product Name: (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide
• Synonyms: (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide
• CAS NO: 937014-94-3
• Molecular Weight: 384.253
• Mol File: 937014-94-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide(937014-94-3)
• EPA Substance Registry System: (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide(937014-94-3)

Safety Data

• Hazardous Substances Data: 937014-94-3(Hazardous Substances Data)

Upstream product

• 144-48-9 iodacetamide 
• 207801-52-3 N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide 
• 1072-97-5 5-bromo-2-pyridylamine 
• 98-59-9 p-toluenesulfonyl chloride 
• 79-07-2 Chloroacetamide 
• 207801-52-3 N-[5-bromo-1H-pyridin-(2Z)-ylidene]-4-methyl-benzenesulfonamide 
• 683-57-8 bromo-acetic acid amide 

Downstream Products

• 947248-52-4 6-bromoimidazole[1,2-a]pyridine-2-amine 
• 1162680-84-3 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)acetamide 
• 947249-08-3 N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-2-yl)acetamide 
• 504413-35-8 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide 

Relevant articles and documents

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.